Non-Hodgkin Lymphoma | Specialty

FDA Approval Insights: Umbralisib in Marginal Zone Lymphoma and Follicular Lymphoma

April 12th 2021

Dr. Fowler discusses the data that served as the basis for the accelerated approval of umbralisib in marginal zone lymphoma and follicular lymphoma, the implications of the regulatory decision on clinical practice, and potential next steps for the PI3Kδ and CK1ε inhibitor.

CAR T-Cell Therapy for R/R Follicular Lymphoma

April 12th 2021

Implications for adding CAR T-cell therapy to the treatment armamentarium for relapsed/refractory follicular lymphoma in the near future.

ZUMA-5 in R/R Follicular Lymphoma

April 12th 2021

Caron A. Jacobson, MD, MMSc, of Dana-Farber Cancer Institute, comments on current data demonstrated by the ZUMA-5 trial in relapsed/refractory follicular lymphoma and the potential use of CAR T-cell therapy moving forward.

Copanlisib/Rituximab Improves PFS in Relapsed Indolent Non-Hodgkin Lymphoma

April 10th 2021

The combination of copanlisib and rituximab was associated with a 48% reduction in the risk of disease progression or death compared with rituximab plus placebo in patients with relapsed indolent non-Hodgkin lymphoma.

Pirtobrutinib Showcases Encouraging Activity in CLL, MCL, and Other B-Cell Malignancies

April 8th 2021

Pirtobrutinib showcased encouraging efficacy with an acceptable safety profile in patients with chronic lymphocytic leukemia or small lymphocytic leukemia, mantle cell lymphoma, and Waldenström macroglobulinemia who previously received a BTK inhibitor.

Dr. Solomon on the Rationale For Liso-Cel in Relapsed/Refractory LBCL

April 7th 2021

Scott R. Solomon, MD, discusses the rationale for examining lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.

Dr. Ghosh on the Potential Advantages of Frontline CAR T-Cell Therapy in DLBCL

April 5th 2021

Nilanjan Ghosh, MD, PhD, discusses the potential advantages of moving CAR T-cell therapy into the frontline setting for patients with diffuse large B-cell lymphoma.

Treating Follicular Lymphoma With Early Progression

April 5th 2021

Approaches to sequencing therapy for patients with follicular lymphoma who experience progression of disease within 24 months (POD24).

Emerging Therapies for R/R Follicular Lymphoma

April 5th 2021

An overview of novel therapies under investigation for the treatment of relapsed/refractory follicular lymphoma and special considerations regarding treating patients with newer, novel agents in the community setting.

Dr. D’Angelo on the Potential Drawbacks of 5-Drug Combinations in B-Cell Lymphoma

April 2nd 2021

Christopher R. D’Angelo, MD, discusses the potential drawbacks of 5-drug combinations in B-cell lymphoma.

x